menu
    • menu
    [{"orgOrder":0,"company":"Tanner Pharma","sponsor":"Tasmanian Alkaloids Pty Ltd","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Clozapine","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Tanner Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Tanner Pharma \/ Tasman Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Tanner Pharma \/ Tasman Pharma"},{"orgOrder":0,"company":"Tanner Pharma","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Approved","graph3":"Tanner Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Tanner Pharma \/ Tanner Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Tanner Pharma \/ Tanner Pharma"},{"orgOrder":0,"company":"Tanner Pharma","sponsor":"Dompe Farmaceutici","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"Cenegermin","moa":"TrkA","graph1":"Ophthalmology","graph2":"Approved","graph3":"Tanner Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tanner Pharma \/ Domp\u00e9 farmaceutici","highestDevelopmentStatusID":"12","companyTruncated":"Tanner Pharma \/ Domp\u00e9 farmaceutici"},{"orgOrder":0,"company":"Tanner Pharma","sponsor":"Ascentage Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Olverembatinib","moa":"BCR-ABL","graph1":"Oncology","graph2":"Approved","graph3":"Tanner Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tanner Pharma \/ Tanner Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Tanner Pharma \/ Tanner Pharma"},{"orgOrder":0,"company":"Tanner Pharma","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Tanner Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tanner Pharma \/ Tanner Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Tanner Pharma \/ Tanner Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Tanner Pharma

    Menu

    Tanner Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Tanner Pharma

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Tanner Pharma

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paclitaxel,Carboplatin

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Recipient : Elevar Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Elevar Therapeutics and Tanner Pharma Group Announce Launch of Global Named Patient Program to Provide Access ...

                            Details : Apealea (paclitaxel micellar) is a patented, water-soluble, intravenously injectable, non-Cremophor based formulation of paclitaxel, which is used to treat breast, ovarian, lung, bladder, prostate, melanoma, and esophageal cancer, as well as other types ...

                            Brand Name : Apealea

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 03, 2023

                            Lead Product(s) : Paclitaxel,Carboplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Recipient : Elevar Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Tanner Pharma

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Tanner Pharma

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olverembatinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Recipient : Ascentage Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ascentage Pharma and Tanner Pharma Group Initiate a Global Innovative Named Patient Program

                            Details : HQP1351 (olverembatinib) is a novel third-generation BCR-ABL inhibitor that can effectively target a spectrum of BCR-ABL mutants, including the T315I mutation, for the treatment of patients with CML intolerant/resistant to at least two TKIs).

                            Brand Name : HQP1351

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 25, 2022

                            Lead Product(s) : Olverembatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Recipient : Ascentage Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Tanner Pharma

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Tanner Pharma

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cenegermin

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Dompe Farmaceutici

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Tanner Pharma Group and Dompé Initiate Distribution Partnership for Oxervate®

                            Details : The agreement names Tanner Pharma Group as the exclusive provider of Oxervate (cenegermin) in countries outside of the United States, Canada, Italy, China and CIS countries (Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Russia, Tajikista...

                            Brand Name : Oxervate

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 30, 2020

                            Lead Product(s) : Cenegermin

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Dompe Farmaceutici

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Tanner Pharma

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Tanner Pharma

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paclitaxel,Carboplatin

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Recipient : Elevar Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Elevar Therapeutics and Tanner Pharma Group Announce Global Named Patient Program to Provide Access to Apealea...

                            Details : Under the terms of the agreement, Tanner will be the exclusive supplier of Apealea to health care providers outside of the U.S. on a named patient basis in countries where Apealea is not yet commercially available.

                            Brand Name : Apealea

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 27, 2020

                            Lead Product(s) : Paclitaxel,Carboplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Recipient : Elevar Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Tanner Pharma

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Tanner Pharma

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clozapine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved

                            Sponsor : Tasmanian Alkaloids Pty Ltd

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Tanner Pharma Group Signs Versacloz Distribution Agreement with Tasman Pharma Inc.

                            Details : Tanner to distribute Versacloz in areas outside of the U.S where the product is not yet registered. Versacloz is indicated for the treatment of severely ill patients with schizophrenia who fail to respond to standard antipsychotic treatment.

                            Brand Name : Versacloz

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 22, 2020

                            Lead Product(s) : Clozapine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved

                            Sponsor : Tasmanian Alkaloids Pty Ltd

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth